Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Cancer drug developer reports loss of $0.23 per share
February 27th, 2006
Array BioPharma, Inc., (ARRY) reported financial results for the second quarter of fiscal 2006. For the second quarter of fiscal 2006, Array reported revenue of $11.9 million, compared to revenue of $12.0 million for the same period in fiscal 2005. Investment in research and development for proprietary drug discovery was $7.8 million, a $2.5 million increase over the same quarter last year, due to additional preclinical and clinical development. Array reported a net loss of $8.7 million, or $0.23 per share, for the second quarter, compared to a net loss of $4.9 million, or $0.16 per share, for the same quarter in fiscal 2005. The reported net loss...
Source: Pharma Business Week (2006-02-27)
|
